Partner in Psychedelic Medicinals
Our mission is to support and enable the commercialization of psychedelic-derived pharmaceuticals for brain and mental health
Media
MagicMed Psilocybin Derivatives Program Announced
January 6, 2021
2020: A Year In Review for Psychedelic Pioneer MagicMed Industries
December 31, 2020
Innovation Pays Off in Psychedelics
December 18, 2020
Just How Big is the Psychedelics Opportunity?
October 27, 2020
3 Psychedelic Business Models (and What’s Best for Investors)
October 22, 2020
How the Psybrary™ Could Revolutionize Psychedelic Drug Discovery
September 24, 2020
Press Releases
Blog
Patenting Natural Products: An Intricate Game
A powerful patent portfolio can be the single most valuable asset of a business. The operative legal driver behind this is straightforward to grasp: patent rights offer the holder of the patent the…
Ibogaine Derivative Suggests Therapeutic Benefit of Psychedelics May Not Require Hallucinatory Activity
Nearly 80 years ago, scientists interested in psychoactive drugs such as LSD, psilocybin and mescaline began investigating their potential for clinical use. Not long after, a series of political and…
MagicMed Industries Partners with University of Calgary to Develop Psybrary™
In pursuit of developing their psychedelic derivative patent library, the Psybrary™, MagicMed is joining forces with the University of Calgary. A research contract was signed that entails the…
Psychedelic Derivatives-From Building Blocks to Blockbuster Drugs
The nascent psychedelic medicine industry has the potential to radically improve modern pharmacopeia with robust new tools. MagicMed’s molecular derivative library, the Psybrary™, is anticipated to…
From Plant-Based to Prescriptible Pills: How Do You Turn Psychedelic Plants Into Medicine
Ancient and indigenous cultures have been utilizing nature’s pharmacy through the therapeutic use of plant medicines since time immemorial. With modern society on the cusp of the psychedelic…